Evolent's 2027 Bet: 25%+ Revenue Growth, but the Profit Margin Gap Is the Real Story

Evolent's 2027 outlook asks investors to separate growth from margin conversion

Evolent is asking investors to evaluate two things at once: a fast-growing platform and a still-unproven margin trajectory. The growth case is clear. Q2 2026 revenue of $652.5 million grew 46.9% year over year, while GAAP diluted loss narrowed to $0.25 per share from $0.44. That supports the view that demand is strong.

Revenue is scaling, but profitability did not follow

The quarter also highlighted the main pressure point. Adjusted EBITDA fell 25.3% even as revenue jumped, and cost of revenue increased 66.2%, faster than the revenue increase. Management also flagged strong continuing demand for our oncology solution, which points to real business momentum, but the quarter did not yet show clean operating leverage. More volume is moving through the system; the profitability payoff still needs to be proved.

Why the 2027 target matters

That is why management's forward view matters so much. Evolent now expects 2027 Adjusted EBITDA outlook at or above $150 million alongside revenue growth of over 25% in 2027. If that happens, investors will have evidence that scale is helping margins improve, not just increasing throughput. If not, the stock remains more of a growth narrative than a converted profitability story.

The core operating question is whether more members create better economics

Evolent already has the scale question partly answered. The harder question is whether each added risk member adds more cash in the register or merely more activity through the business.

Why contract quality matters more than contract count

In simple terms, more members only matter if they come with better clinical management, lower unnecessary spending, and a operating model that does not need proportionally more cost to handle them. That is the mechanism that should widen margins over time. If that mechanism works, growth compounds into earnings. If not, revenue can rise while profit stays stuck.

Demand looks durable, but the payoff still needs proof

There are reasons to take the demand story seriously. Evolent said it executed on its earnings targets in 2025, continued to grow market share, and renewed customers at strong rates. It also pointed to roughly 30% revenue growth for 2026 as evidence of model durability. That matters because contract-heavy service businesses compound when clients stay and expand.

Management also pointed to strong continuing demand for our oncology solution when laying out the next leg of growth. That suggests the pipeline is not dependent on a single launch cycle. It is still too early to call that demand a full margin story, but it does support the case for a broader, more durable revenue base.

What would validate or weaken the 2027 margin thesis

There is reason to give management the benefit of the doubt. Last year, the company said year-end 2026 margins should quickly step-up. Recent results have made that less easy to assume. A higher medical expense ratio and cost growth running ahead of revenue show that this business can keep getting bigger before it gets cleaner.

The quarter also reminded investors that not every bottom-line improvement reflects underlying operating leverage. According to the reported results, The narrower GAAP loss attributable to common shareholders primarily reflected the absence of $31.2 million in preferred dividends and accretion recorded in Q2 2025. That does not erase the growth story, but it does argue for a more selective read of the quarter's earnings line.

The clearest signals to watch

The next updates matter more than the headline growth rate. The clearest validation signals would be:

• margin walk-forward, rather than another quarter of cost growth outrunning revenue
• evidence that new and expanded contracts are improving the profit mix, not just the top line
• clearer proof that oncology and other solution demand are translating into better performance over time

When the thesis gets less compelling

The weakness signal is straightforward: if revenue keeps compounding but adjusted EBITDA margins continue to drift lower, the 2027 target becomes harder to trust. In that scenario, the growth narrative would remain intact while the profitability case would keep falling behind.

Evolent still looks like a high-upside watch, but not a straightforward one. The quarter supported the growth story; it did not fully settle the margin story.